Church attendance associated with late HIV diagnosis among US MSM
GAT Portugal
Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated
Harm reduction works: extremely low HIV incidence over almost 20 years among people who inject drugs in Australia
Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat
Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection
Rifampicin dose can be increased safely in TB treatment, may shorten duration
Audit shows many high HIV prevalence areas in England are failing to expand HIV testing
Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study
